Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pulse Biosciences said its NANOPULSE-AF clinical study reached its target enrollment of 164 evaluable patients across 15 sites. The company said the study is evaluating its nPulse Cardiac Catheter System for treatment of drug-resistant, symptomatic paroxysmal atrial fibrillation.
Pulse Biosciences said it achieved the enrollment target in its NANOPULSE-AF IDE pivotal clinical study evaluating the nPulse cardiac catheter system for atrial fibrillation treatment.
Pulse Biosciences announced its NANOPULSE-AF Study evaluating the nPulse™ Cardiac Catheter System has reached its enrollment target of 164 evaluable patients across 15 clinical sites. The study achieved enrollment three months ahead of its original nine-month timeline.
Pulse Biosciences announced its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites. The study is evaluating the nPulse™ Cardiac Catheter System for the treatment of atrial fibrillation using the company's nano-PFA technology.